Trial Profile

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glofitamab (Primary) ; Obinutuzumab (Primary) ; Tocilizumab (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms STARGLO
Sponsors Roche

23 May 2025 Two year follow up data from this trial presented in the Roche Media Release
23 May 2025 According to Genentech media release, data from this trial will be presented in an oral session at the 61st American Society of Clinical Oncology (ASCO)
23 May 2025 Results presented in the Genentech Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com